PD-L1 tumour proportion score (TPS) assessed using 22C3 antibody was balanced between the treatment groups and was positive (>1%) in 88/258 (34.1%) of the randomised patients, with 73/258 (28.3%) scoring between 1–49%, and 15/258 (5.8%) >50%. The gene discussed is CD274; the disease is neoplasm.